Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
With comparable levels of blood pressure among the three groups, the usage rate of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in the diabetic population was the highest, while the usage rates of dihydropyridine calcium channel blockers (DHP-CCB) and thiazide-like diuretics were comparable in those three groups, suggesting the highest degree of hypertension in the T2DM group.Clinical characteristics of the study participants.ParameterNormoglycemia (n = 18)Prediabetes (n = 27)p-value&T2DM (n = 73)p-value&&Age (years)58.6 ± 9.061.6 ± 7.50.23960.0 ± 7.50.441Gender (% female)11 (61.1)20 (74.1)0.35745 (59.2)0.385BMI (kg/m2)24.3 ± 2.624.6 ± 3.80.81225.9 ± 4.10.160SBP (mmHg)126.8 ± 14.1132.9 ± 12.40.131131.2 ± 14.70.350DBP (mmHg)80.9 ± 9.476.4 ± 10.10.14075.4 ± 9.60.102IFG duration (years): 3.2 (2.2 to 4.3): : : DM duration (years): : : 5.7 (4.7 to 6.9): Microvascular complications (%): : : 40 (52.6): Macrovascular complication (%): : : 10 (13.2): FPG (mg/dL)89.9 (86.7 to 93.2)102.1 (97.9 to 106.4)< 0.001135.5 (126.9 to 144.6)< 0.001HbA1c (%): 5.9 ± 0.5 to 7.4 ± 1.4< 0.001eGFR (ml/min)81.7 ± 18.187.8 ± 14.80.23080.2 ± 17.70.151Triglycerides (mg/dL)80.7 (67.0 to 101.4)90.4 (77.6 to 108.1)0.368108.9 (99.6 to 120.1)0.006LDL-C* (mg/dL)113.9 (98.7 to 131.5)97.4 (87.1 to 108.9)0.07887.6 (80.5 to 95.3)0.012HDL-C# (mg/dL)67.1 ± 27.060.0 ± 14.80.33452.6 ± 13.60.002Anti-hyperglycemic agents [n (%use)] Metformin01 (3.7)1.00069 (94.5)< 0.001 Sulfonylureas00: 18 (24.7)0.001 Insulin00: 7 (9.6)0.171 Others00: 7 (9.6)0.171Drugs [n (% use)] ACEI or ARB**5 (27.8)12 (46.2)0.21853 (72.6)0.001 DHP-CCB##11 (61.1)9 (34.6)0.08341 (56.2)0.119 Thiazide-like diuretics3 (16.7)6 (23.1)0.60420 (27.4)0.624 Statins10 (55.6)15 (55.6)1.00063 (86.3)0.001 Fibrate2 (11.1)3 (11.1)1.0004 (5.5)0.414 Calcium and vitamin D3 (16.7)4 (14.8)0.8745 (6.8)0.180FRAX: 10-year risk of hip fractures (FRAX-H) (%)0.4 (0.2 to 0.7)0.7 (0.4 to 1.2)0.1400.4 (0.3 to 0.5)0.143FRAX:10-year risk of osteoporotic fractures (FRAX-O) (%)2.3 (1.9 to 3.0)3.0 (2.4 to 4.0)0.1412.4 (2.1 to 2.6)0.128Pentosidine (ng/mL)3.6 (2.8 to 4.6)2.5 (2.0 to 3.1)0.0293.4 (2.9 to 4.1)0.095Soluble RAGE (sRAGE) (pg/mL)531.7 (414.7 to 681.6)459.9 (369.8 to 572.0)0.375460.3 (415.4 to 510.1)0.498sRAGE-Pentosidine ratio (pg/ng)146.2 (102.3 to 208.9)182.2 (132.8 to 250.0)0.352134.3 (110.5 to 163.2)0.252Interleukin-1β (pg/mL)0.5 (0.3 to 0.8)0.5 (0.3 to 0.7)0.8440.4 (0.3 to 0.5)0.156Tumor necrosis factor-α (pg/mL)0.7 (− 0.4 to 2.2)2.2 (1.3 to 3.3)0.0582.1 (1.6 to 2.6)0.036&Comparison between groups with normoglycemia and prediabetes.&& Comparison among groups with normoglycemia, prediabetes and T2DM.*LDL-C: low-density lipoprotein cholesterol; #HDL-C: high-density lipoprotein cholesterol;**ACEI: angiotensin-converting enzyme inhibitors; **ARB: angiotensin II receptor blockers; ##DHP-CCB: dihydropyridine calcium channel blockers.
Source: Demographic data, clinical characters, and biochemical parameters of study participants. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Laboratory / cell research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
This cross-sectional study included 18 normoglycemic, 27 prediabetic, and 73 T2DM to determine osteogenic differentiation across the continuum of dysglycemia and to construct a model to predict the fate of osteoprogenitor cells.
Source: Abstract.
To induce osteogenic differentiation, the adhered cells were cultured in a non-osteogenic-inducing medium until they reached 50% confluence.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
The trajectory of osteoblast progenitor cells in patients with type 2 diabetes and the predictive model for their osteogenic differentiation ability
Cross-sectional study · Scientific Reports · 2023
Original publication title
The trajectory of osteoblast progenitor cells in patients with type 2 diabetes and the predictive model for their osteogenic differentiation ability
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
The fate of osteoprogenitor cells along with the progression of type 2 diabetes (T2DM) and factors determining the fate of those cells remains to be elucidated. This cross-sectional study included 18 normoglycemic, 27 prediabetic, and 73 T2DM to determine osteogenic differentiation across the continuum of dysglycemia and to construct a model to predict the fate of osteoprogenitor cells. This study demonstrated a preserved osteogenic differentiation ability of peripheral blood-derived mononuclear cells (PBMC) isolated from normoglycemic and prediabetic but a progressive decline in their osteogenic differentiation during the progression of T2DM.
The rate of osteogenic differentiation rapidly declined by 4 to 7% annually during the first 10 years of diabetes and then slowed down. A predictive model composed of three independent risk factors, including age, duration of diabetes, and glomerular filtration rate, demonstrated an AuROC of 0.834. With a proposed cut-off of 21.25, this model had 72.0% sensitivity, 87.5% specificity, and 78.9% accuracy in predicting the fate of osteoprogenitor cells. In conclusion, this study provided a perspective on the osteogenic differentiation ability of the osteoprogenitor cells across a continuum of dysglycemia and a predictive model with good diagnostic performance for the prediction of the fate of osteoprogenitor cells in patients with T2DM.
Authors’ abstract
The fate of osteoprogenitor cells along with the progression of type 2 diabetes (T2DM) and factors determining the fate of those cells remains to be elucidated. This cross-sectional study included 18 normoglycemic, 27 prediabetic, and 73 T2DM to determine osteogenic differentiation across the continuum of dysglycemia and to construct a model to predict the fate of osteoprogenitor cells. This study demonstrated a preserved osteogenic differentiation ability of peripheral blood-derived mononuclear cells (PBMC) isolated from normoglycemic and prediabetic but a progressive decline in their osteogenic differentiation during the progression of T2DM.
The rate of osteogenic differentiation rapidly declined by 4 to 7% annually during the first 10 years of diabetes and then slowed down. A predictive model composed of three independent risk factors, including age, duration of diabetes, and glomerular filtration rate, demonstrated an AuROC of 0.834. With a proposed cut-off of 21.25, this model had 72.0% sensitivity, 87.5% specificity, and 78.9% accuracy in predicting the fate of osteoprogenitor cells. In conclusion, this study provided a perspective on the osteogenic differentiation ability of the osteoprogenitor cells across a continuum of dysglycemia and a predictive model with good diagnostic performance for the prediction of the fate of osteoprogenitor cells in patients with T2DM.
Publication and source details
Original title: The trajectory of osteoblast progenitor cells in patients with type 2 diabetes and the predictive model for their osteogenic differentiation ability
Mattabhorn Phimphilai; Peraphan Pothacharoen; Nipon Chattipakorn; Prachya Kongtawelert
Scientific Reports · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.the Thailand Research FundMRG5480270Phimphilai Mattabhorn Merckthe NSTDA Research Chair grant from the National Science and Technology Development Agency Thailandthe Chiang Mai University Center of Excellence AwardRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T20:37:52.396698+00:00
DOI: 10.1038/s41598-023-29677-8 · PMC9911595